美国血液学会COVID-19患者血栓预防抗凝应用活指南:2022年1月更新——急性病患者治疗强度抗凝的应用
美国血液学会(ASH)基于GRADE方法制定活指南,2022年1月更新新增一条有条件推荐:对无疑似或确诊静脉血栓栓塞症(VTE)的COVID-19相关急性病患者,倾向使用治疗强度而非预防强度抗凝。该推荐基于极低质量证据,强调个体化评估血栓与出血风险,并指出肝素(普通肝素或低分子量肝素)可能因证据较多而优先选用。
要点
- 对无疑似或确诊VTE的COVID-19相关急性病患者,ASH有条件推荐治疗强度优于预防强度抗凝。
- 该推荐基于极低质量证据,强调需个体化评估血栓和出血风险。
- 肝素(普通肝素或低分子量肝素)可能因证据较多而优先选用。
核心结论
- ASH对无疑似或确诊VTE的COVID-19相关急性病患者,有条件推荐治疗强度抗凝优于预防强度抗凝,该推荐基于极低质量证据。
- 强调需个体化评估血栓和出血风险,并指出肝素(普通肝素或低分子量肝素)可能因证据较多而优先选用。
- 指出需开展更多高质量随机对照试验比较不同抗凝强度。
研究设计与样本
- ASH成立多学科指南小组,包括患者代表,并采取措施减少利益冲突偏倚。
- 麦克马斯特大学GRADE中心支持指南制定过程并完成截至2021年11月的系统证据评价。
- 小组按临床问题和结局对临床医生和患者的重要性排序,采用GRADE方法评估证据并形成推荐,推荐经公开征求意见。
- 本指南为2021年2月发布的活指南更新。
主要发现
- 小组新增一条有条件推荐:对无疑似或确诊VTE的COVID-19相关急性病患者,倾向治疗强度抗凝优于预防强度抗凝。
- 该有条件推荐基于极低质量证据。
关键数值与推荐
- 有条件推荐:对无疑似或确诊VTE的COVID-19相关急性病患者,治疗强度抗凝优于预防强度抗凝。
- 肝素(普通肝素或低分子量肝素)可能因证据较多而优先选用。
临床怎么用
- 对无疑似或确诊VTE的COVID-19相关急性病患者,ASH有条件推荐使用治疗强度抗凝而非预防强度抗凝。
- 强调需个体化评估血栓和出血风险。
- 肝素(普通肝素或低分子量肝素)可能因证据较多而优先选用。
局限性
- 该有条件推荐基于极低质量证据。
- 强调需开展更多高质量随机对照试验比较不同抗凝强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19-related acute illness is associated with an increased risk of venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation in patients with COVID-19. METHODS: ASH formed a multidisciplinary guideline panel that included patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process and performed systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines. RESULTS: The panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19-related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of evidence with this class of anticoagulants. CONCLUSION: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.
引用
- Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv. 2022. PMID: 35503027. doi:10.1182/bloodadvances.2022007561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。